HPV type 18 is more oncopotent than HPV16 in uterine cervical carcinogenesis although HPV16 is the prevalent type in Chennai, India

Indian Journal of Cancer

Volumn 46, Issue 3, 2009, Pages 203-207

  Berlin Grace, V M ^a  

^a KARUNYA UNIVERSITY   (India)

Author keywords

HPV 18 potent type; HPV prevalence and risk; Invasive cancer; PCR; Uterine cervical lesions

Indexed keywords

VIRUS DNA;

ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; NONHUMAN; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PREVALENCE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; VIRUS TYPING;

CASE-CONTROL STUDIES; CERVIX UTERI; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INDIA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS;

EID: 67651165307     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.52954     Document Type: Article

References (18)

1. National cancer registry programme. ICMR; Report of population based cancer surveys at Bangalore, Chennai and Mumbai: Coordinating unit of NCRP. Bangalore: 2000. p. 14.
2. Shanta V, Krishnamurthi S, Gajalakshmi CK, Swaminathan R, Ravi-chandran K. Epidemiology of cancer of the cervix: global and national perspective. J Indian Med Assoc 2000;98:49-52.
3. Nair P, Nair KM, Jayaprakash PG, Pillai MR. Decreased programmed cell death in the uterine cervix associated with high risk human papilloma virus infection. Pathol Oncol Res 1999;5:95-103.
4. Bosch FX, de Sanjosé S. Chapter 1: Human Papillomavirus and Cervical Cancer-Burden and Assessment of Causality. J Natl Cancer Inst Monogr 2003;31:3-13.
5. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
6. Franceschi S, Rajkumar T, Vaccarella S, Gajalakshmi V, Sharmila A, Snijders PJ, et al. Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. Int J Cancer 2003;107:127-33.
7. Morrison EA, Ho GY, Vermund SH, Goldberg GL, Kadish AS, Kelley KF, et al. Human papilloma virus infection and other risk factors for cervical neoplasia: a case- control study. Int J Cancer 1991;49:6-13.
8. Chan MK, Lau KM, Tsui Y, Wong FW, Huang DP. Human papilloma virus infection in Hong Kong Chinese women with normal and abnormal cervix-detection by polymerase chain reaction method on cervical scrapes. Gynecol Oncol 1996;60: 217-23.
9. Cass I, Baldwin RL, Karlan BY. Molecular advances in gynecologic oncology. Curr Opin Oncol 1999;11:394-400.
10. Soloman D, Schiffman M, Tarone R; ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined signifi cance baseline results from a randomized trial. J Natl Cancer Ins 2001;93:293-9.
11. Riou G, Favre M, Jeannel D, Bourhis J, Le Doussal V, Orth G. Association between poor prognosis in early stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 1990;335:1171-4.
12. zur Hausen H. Human papilloma viruses in the pathogenesis of anogenital cancer. Virology 1991;184:9-13.
13. Berlin Grace VM, Niranjali Devaraj S, Radhakrishnan Pillai M, Devaraj H. HPV Induced Carcinogenesis of the Uterine Cervix is Associated with Reduced Serum ATRA level. Gynecol Oncol 2006;103:113-9.
14. Grace VM, Shalini JV, lekha TT, Devaraj SN, Devaraj H. Co-overex-pression of p53 and bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2003;91:51-8.
15. Hendrix SL. Assessing Human Papillomavirus Vaccine Effi cacy and Safety. J Am Osteopath Assoc 2008;108:S8-12.
16. Duttagupta C, Sengupta S, Roy M, Sengupta D, Chakraborty S, Bhattacharya P, et al. Oncogenic human papillomavirus (HPV) infection and uterine cervical cancer: a screening strategy in the perspective of rural India. Eur J Cancer Prev 2002;11:447-56.
17. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
18. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Effi cacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27